Get the Stockscreener App
86.60
1.70%
-1.50
Edwards Lifesciences Corp stock is traded at $86.60, with a volume of 4.00M.
It is down -1.70% in the last 24 hours and down -3.00% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$88.10
Open:
$88.21
24h Volume:
4.00M
Relative Volume:
0.99
Market Cap:
$49.92B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
47.05
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
+1.63%
1M Performance:
-3.00%
6M Performance:
+9.55%
1Y Performance:
+19.20%
1-Day Range:
$86.08
$88.40
1-Week Range:
$84.55
$88.41
52-Week Range:
$72.42
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-26 | Initiated | Barclays | Overweight |
| Jul-28-26 | Initiated | UBS | Buy |
| Jul-24-26 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death - Benzinga
Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corporation $EW Stock Sold by Ninety One UK Ltd - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Ninety One North America Inc. - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Earnings Preview: What to Expect - Yahoo Finance
Edwards Lifesciences Earnings Preview: What to Expect - Barchart.com
Edwards Lifesciences Earnings Preview: What to Expect - inkl
Edwards Lifesciences Corporation (EW) Options ChainYahoo Finance - Yahoo! Finance Canada
Edwards Lifesciences Corporation (EW) Options Chain - Yahoo! Finance Canada
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences CVP Daniel Lippis sells $53k in stock - Investing.com
Edwards Lifesciences Corp (EW) Insider Daniel Lippis Sells 619 S - GuruFocus
Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Is Edwards Lifesciences (NYSE:EW) Entering A Stronger Phase? - Kalkine Media
Why Edwards Lifesciences (EW) Stock Is Falling Today - Quiver Quantitative
UBS reiterates Edwards Lifesciences stock rating on endpoint expectations - Investing.com
Edwards Lifesciences (EW) Stock Forecast and Price Target 2026 $EW - MarketBeat
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise? - Zacks Investment Research
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - BioSpace
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - Yahoo Finance
Edwards Lifesciences Corp (CEUX:EWLd) Stock Earnings Transcripts - GuruFocus
Edwards Lifesciences (NYSE:EW) Share Price Breaks Above Two Hundred Day Moving AverageWhat's Next? - marketbeat.com
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
What Does Expanded TAVR Coverage Mean for Edwards Lifesciences (NYSE:EW)? - Kalkine Media
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating - Yahoo Finance
Edwards Lifesciences to Host Investor Event in Conjunction With TCT - Yahoo Finance
Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve - Benzinga
JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $100, Keeps Overweight Rating - marketscreener.com
Edwards Lifesciences (NYSE:EW) Stock Forecast & Analyst Predictions - Simply Wall Street
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients - BioSpace
Edwards Lifesciences wins FDA approval for AUTUS - Mugglehead Investment Magazine
Edwards Lifesciences (EW) Gains FDA Clearance for AUTUS Size-Adj - GuruFocus
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Receives FDA Approval For AUTUS Size-Adjustable Valve - marketscreener.com
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
ETFs Investing in Edwards Lifesciences Corporation Stocks - tradingview.com
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27 - MarketBeat
Claim your share of the $39 million Edwards Lifesciences securities class action settlement - Claim Depot
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
EW IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class ActionEW - TMX Newsfile
Andra AP fonden Boosts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions - Yahoo Finance
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edwards Lifesciences Corp Stock (EW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lippis Daniel J. | CVP, TAVR |
Oct 08 '26 |
Sale |
85.65 |
619 |
53,017 |
40,034 |
| Lippis Daniel J. | CVP, TAVR |
Sep 11 '26 |
Option Exercise |
72.68 |
619 |
44,989 |
40,653 |
| Lippis Daniel J. | CVP, TAVR |
Sep 11 '26 |
Sale |
87.51 |
619 |
54,169 |
40,034 |
| Dahl Andrew M. | SVP, Corporate Controller |
Aug 31 '26 |
Sale |
91.06 |
544 |
49,534 |
14,868 |
| Dahl Andrew M. | Officer |
Aug 31 '26 |
Proposed Sale |
91.06 |
544 |
49,534 |
0 |
| Bruls Annette | CVP, EMEACLA |
Aug 28 '26 |
Sale |
89.98 |
2,644 |
237,907 |
17,984 |
| Bruls Annette | Officer |
Aug 28 '26 |
Proposed Sale |
89.98 |
2,644 |
237,907 |
0 |
| Markowitz Wayne | CVP, JAPAC |
Aug 26 '26 |
Sale |
91.47 |
1,240 |
113,417 |
20,294 |
| Markowitz Wayne | Officer |
Aug 26 '26 |
Proposed Sale |
91.47 |
1,240 |
113,417 |
0 |
| Chopra Daveen | Officer |
Aug 26 '26 |
Proposed Sale |
91.02 |
31,800 |
2,894,440 |
0 |
0.57%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):